The Turner Syndrome drugs in development market research report provides comprehensive information on the therapeutics under development for Turner Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Turner Syndrome. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Turner Syndrome - Drugs In Development, 2023

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Turner Syndrome and features dormant and discontinued products.

GlobalData tracks eight drugs in development for Turner Syndrome by eight companies/universities/institutes. The top development phase for Turner Syndrome is preclinical with three drugs in that stage. The Turner Syndrome pipeline has eight drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Turner Syndrome pipeline products market are: Changchun GeneScience Pharmaceutical, Xiamen Amoytop Biotech and Ascendis Pharma.

The key targets in the Turner Syndrome pipeline products market include Growth Hormone Receptor (Somatotropin Receptor or GHR), Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1), and Matrilin 3 (MATN3).

The key mechanisms of action in the Turner Syndrome pipeline product include Growth Hormone Receptor (Somatotropin Receptor or GHR) Agonist with six drugs in Phase III. The Turner Syndrome pipeline products include three routes of administration with the top ROA being Subcutaneous and three key molecule types in the Turner Syndrome pipeline products market including Recombinant Protein, and Subunit Vaccine.

Turner Syndrome overview

Turner syndrome, also referred to as congenital ovarian hypoplasia syndrome, is a chromosomal disorder that affects development in females. It results when a female’s cells have one normal X chromosome and the other sex chromosome is either missing or structurally altered. About half of the population with Turner syndrome have monosomy X (45,XO). The other 50% of the population has a mosaic chromosomal component (45,X with mosaicism). Turner syndrome is typically not inherited, but it can be inherited in rare cases. Some patients with Turner syndrome can have a Y chromosome mosaicism. Although not a cause of Turner syndrome, SHOX (short stature homeobox-containing gene on the X- chromosome) is associated with the short stature found in Turner syndrome.

For a complete picture of Turner Syndrome’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.